View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Eventsco.don 過去の業績過去 基準チェック /06co.donの収益は年間平均-15.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間17.5% 10.7%割合で 増加しています。主要情報-15.38%収益成長率1.35%EPS成長率Biotechs 業界の成長-14.59%収益成長率10.68%株主資本利益率-214.21%ネット・マージン-143.55%前回の決算情報30 Jun 2022最近の業績更新お知らせ • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.お知らせ • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022お知らせ • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.お知らせ • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021すべての更新を表示Recent updatesお知らせ • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.お知らせ • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.お知らせ • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022お知らせ • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022お知らせ • May 02co.don AG Announces Resignation of Hans-B. Bauerfeind as Chairman of the Supervisory Board for Health ReasonsProfessor Hans-B. Bauerfeind has informed co.don AG that he is resigning from his chairmanship of the Supervisory Board for health reasons at the age of 81 and is retiring from the Supervisory Board with immediate effect. The office of Chairman of the Supervisory Board will be taken over by Mr. Thommy Stählin, long-time member of the Supervisory Board and former Deputy Chairman of the Supervisory Board.Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 321% above last closing price of €1.39. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.お知らせ • Feb 26co.don AG Announces Resignation of Hans-Joachim Simons as Member of the Executive Board Effective February 28, 2022In agreement with the Supervisory Board, Dr. Hans-Joachim Simons has resigned from his position as a member of the Executive Board of CO.DON AG with effect from the end of February 28, 2022, in order to pursue new professional responsibilities.Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 245% above last closing price of €1.69. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.分析記事 • Oct 06Here's Why co.don (ETR:CNW) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Major Estimate Revision • Aug 07Consensus EPS estimates fall to -€0.29The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €11.1m to €10.0m. Losses expected to increase from -€0.21 to -€0.29. Biotechs industry in Germany expected to see average net income decline 12% next year. Consensus price target of €4.20 unchanged from last update. Share price fell 11% to €1.12 over the past week.Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 193% above last closing price of €1.44. Stock is up 15% over the past year.お知らせ • Jun 04co.don Ag Announces Marketing Authorisation Granted for Spherox in the United KingdomThe MHRA (Medicines and Healthcare products Regulatory Agency) has granted marketing authorisation for the autologous medicinal product Spherox marketed by CO.DON AG, thus completing the BREXIT-related transition of the medicinal product, which has already been approved throughout the EU. The regulatory authority MHRA regulates the approval of medicines, medical devices and blood components for transfusions in the UK. The re-approval process had become necessary due to the UK's withdrawal from the European Union, as the scope of the original approval only covered EU member states.Major Estimate Revision • May 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. Forecast loss of -€0.21 per share in 2021, versus previous forecasts of €0.15 per share. Revenue forecast unchanged from €11.1m at last update. Biotechs industry in Germany expected to see average net income growth of 0.4% next year. Consensus price target of €3.80 unchanged from last update. Share price rose 4.9% to €1.07 over the past week.お知らせ • May 22co.don AG Receives Positive Vote of Committee for Medicinal Products for Human Use of the EMACO.DON AG received the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on theapproval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents. The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications. With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm ^ 2 is now also possible in adolescents with closed growth plates in addition to adult patients.分析記事 • May 06Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 29co.don AG Technology Transfer Process Gets Green Light from EMAThe European Medicines Agency has authorized the new manufacturing site in Leipzig for CO.DON AG. The Leipzig site is now formally approved for the manufacture, quality control and marketing of Spherox for the EU. This means that all the official requirements set by the EMA to produce the pharmaceutical product in Leipzig and its distribution within the EU market have been met. The technology transfer process will be completed with a routine inspection by the state authority for Saxony, which The company expects to take place in summer 2021. Spherox production is planned to start in Leipzig in August/September 2021, whereby both sites will initially produce for the EU market in parallel.分析記事 • Mar 15Will co.don (ETR:CNWK) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Feb 08Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Longco.don AG ( ETR:CNWK ) is possibly approaching a major achievement in its business, so we would like to shine some...お知らせ • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021分析記事 • Jan 04co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.While it may not be enough for some shareholders, we think it is good to see the co.don AG ( ETR:CNWK ) share price up...お知らせ • Dec 19CO.DON AG Appoints Achim Simons to Executive BoardThe Supervisory Board of CO.DON AG has appointed Dr. Achim Simons to the Executive Board of CO.DON AG with effect from 1 January 2021. Dr. Simons was previously a surgeon.Is New 90 Day High Low • Oct 13New 90-day low: €0.95The company is down 28% from its price of €1.32 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.Is New 90 Day High Low • Sep 19New 90-day low: €0.96The company is down 23% from its price of €1.24 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.63 per share.収支内訳co.don の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XTRA:CNW 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 2210-1411031 Mar 2210-1211031 Dec 2110-911030 Sep 218-1011030 Jun 217-1110031 Mar 216-1310031 Dec 206-1410030 Sep 206-1511030 Jun 207-1611031 Mar 207-1410031 Dec 197-1310030 Sep 196-119030 Jun 196-98031 Mar 196-78031 Dec 186-68030 Sep 186-78030 Jun 186-88031 Mar 186-87031 Dec 176-77030 Sep 176-66030 Jun 176-56031 Mar 176-45031 Dec 166-45030 Sep 166-35030 Jun 166-35031 Mar 165-34031 Dec 155-340質の高い収益: CNWは現在利益が出ていません。利益率の向上: CNWは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CNWは利益が出ておらず、過去 5 年間で損失は年間15.4%の割合で増加しています。成長の加速: CNWの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CNWは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 50.1% ) と比較することは困難です。株主資本利益率高いROE: CNWは現在利益が出ていないため、自己資本利益率 ( -214.21% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/28 03:38終値2022/09/30 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋co.don AG これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Peter-Thilo HaslerSphene Capital GmbHUlrich HuwaldWarburg Research GmbHHarald HofWarburg Research GmbH
お知らせ • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022
Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.
お知らせ • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022
お知らせ • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
お知らせ • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021
お知らせ • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.
お知らせ • Aug 26co.don AG to Report First Half, 2022 Results on Sep 30, 2022co.don AG announced that they will report first half, 2022 results on Sep 30, 2022
Reported Earnings • Jul 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.
お知らせ • Jul 09+ 1 more updateco.don AG to Report Fiscal Year 2021 Results on Jul 07, 2022co.don AG announced that they will report fiscal year 2021 results on Jul 07, 2022
お知らせ • May 05co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022
お知らせ • May 02co.don AG Announces Resignation of Hans-B. Bauerfeind as Chairman of the Supervisory Board for Health ReasonsProfessor Hans-B. Bauerfeind has informed co.don AG that he is resigning from his chairmanship of the Supervisory Board for health reasons at the age of 81 and is retiring from the Supervisory Board with immediate effect. The office of Chairman of the Supervisory Board will be taken over by Mr. Thommy Stählin, long-time member of the Supervisory Board and former Deputy Chairman of the Supervisory Board.
Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 321% above last closing price of €1.39. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
お知らせ • Feb 26co.don AG Announces Resignation of Hans-Joachim Simons as Member of the Executive Board Effective February 28, 2022In agreement with the Supervisory Board, Dr. Hans-Joachim Simons has resigned from his position as a member of the Executive Board of CO.DON AG with effect from the end of February 28, 2022, in order to pursue new professional responsibilities.
Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 245% above last closing price of €1.69. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
分析記事 • Oct 06Here's Why co.don (ETR:CNW) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Major Estimate Revision • Aug 07Consensus EPS estimates fall to -€0.29The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €11.1m to €10.0m. Losses expected to increase from -€0.21 to -€0.29. Biotechs industry in Germany expected to see average net income decline 12% next year. Consensus price target of €4.20 unchanged from last update. Share price fell 11% to €1.12 over the past week.
Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 193% above last closing price of €1.44. Stock is up 15% over the past year.
お知らせ • Jun 04co.don Ag Announces Marketing Authorisation Granted for Spherox in the United KingdomThe MHRA (Medicines and Healthcare products Regulatory Agency) has granted marketing authorisation for the autologous medicinal product Spherox marketed by CO.DON AG, thus completing the BREXIT-related transition of the medicinal product, which has already been approved throughout the EU. The regulatory authority MHRA regulates the approval of medicines, medical devices and blood components for transfusions in the UK. The re-approval process had become necessary due to the UK's withdrawal from the European Union, as the scope of the original approval only covered EU member states.
Major Estimate Revision • May 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. Forecast loss of -€0.21 per share in 2021, versus previous forecasts of €0.15 per share. Revenue forecast unchanged from €11.1m at last update. Biotechs industry in Germany expected to see average net income growth of 0.4% next year. Consensus price target of €3.80 unchanged from last update. Share price rose 4.9% to €1.07 over the past week.
お知らせ • May 22co.don AG Receives Positive Vote of Committee for Medicinal Products for Human Use of the EMACO.DON AG received the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on theapproval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents. The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications. With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm ^ 2 is now also possible in adolescents with closed growth plates in addition to adult patients.
分析記事 • May 06Health Check: How Prudently Does co.don (ETR:CNWK) Use Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 29co.don AG Technology Transfer Process Gets Green Light from EMAThe European Medicines Agency has authorized the new manufacturing site in Leipzig for CO.DON AG. The Leipzig site is now formally approved for the manufacture, quality control and marketing of Spherox for the EU. This means that all the official requirements set by the EMA to produce the pharmaceutical product in Leipzig and its distribution within the EU market have been met. The technology transfer process will be completed with a routine inspection by the state authority for Saxony, which The company expects to take place in summer 2021. Spherox production is planned to start in Leipzig in August/September 2021, whereby both sites will initially produce for the EU market in parallel.
分析記事 • Mar 15Will co.don (ETR:CNWK) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Feb 08Analysts Expect Breakeven For co.don AG (ETR:CNWK) Before Longco.don AG ( ETR:CNWK ) is possibly approaching a major achievement in its business, so we would like to shine some...
お知らせ • Jan 05+ 1 more updateco.don AG to Report Fiscal Year 2020 Results on Apr 30, 2021co.don AG announced that they will report fiscal year 2020 results on Apr 30, 2021
分析記事 • Jan 04co.don's(ETR:CNWK) Share Price Is Down 85% Over The Past Three Years.While it may not be enough for some shareholders, we think it is good to see the co.don AG ( ETR:CNWK ) share price up...
お知らせ • Dec 19CO.DON AG Appoints Achim Simons to Executive BoardThe Supervisory Board of CO.DON AG has appointed Dr. Achim Simons to the Executive Board of CO.DON AG with effect from 1 January 2021. Dr. Simons was previously a surgeon.
Is New 90 Day High Low • Oct 13New 90-day low: €0.95The company is down 28% from its price of €1.32 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share.
Is New 90 Day High Low • Sep 19New 90-day low: €0.96The company is down 23% from its price of €1.24 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.63 per share.